东诚药业：下属公司获药物临床试验批准通知书

Group 1 - The core point of the article is that Dongcheng Pharmaceutical's subsidiary, LNC PHARMA PTE. LTD., has received FDA approval for a clinical trial of the drug 225Ac-LNC1011, which is intended for treating advanced prostate cancer patients with PSMA-positive expression [1] Group 2 - The clinical trial is set to begin shortly, indicating progress in the development of this potential treatment [1]